Cancer Epidemiology Biomarkers & Prevention最新文献

筛选
英文 中文
Evaluation of multiple breast cancer polygenic risk score panels in women of Latin American heritage.
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-03 DOI: 10.1158/1055-9965.EPI-24-1247
Xiaosong Huang, Paul C Lott, Donglei Hu, Valentina A Zavala, Zoeb N Jamal, Tatiana Vidaurre, Sandro Casavilca-Zambrano, Jeannie Navarro Vásquez, Carlos A Castañeda, Guillermo Valencia, Zaida Morante, Mónica Calderón, Julio E Abugattas, Hugo A Fuentes, Ruddy Liendo-Picoaga, Jose M Cotrina, Silvia P Neciosup, Patricia Rioja Viera, Luis A Salinas, Marco Galvez-Nino, Scott Huntsman, Sixto E Sanchez, Michelle A Williams, Bizu Gelaye, Ana P Estrada-Florez, Guadalupe Polanco-Echeverry, Magdalena Echeverry, Alejandro Velez, Jenny A Carmona-Valencia, Mabel E Bohorquez-Lozano, Javier Torres, Miguel Cruz, Weang-Kee Ho, Soo Hwang Teo, Mei Chee Tai, Esther M John, Christopher A Haiman, David V Conti, Fei Chen, Gabriela Torres-Mejía, Lawrence H Kushi, Susan L Neuhausen, Elad Ziv, Luis G Carvajal-Carmona, Laura Fejerman
{"title":"Evaluation of multiple breast cancer polygenic risk score panels in women of Latin American heritage.","authors":"Xiaosong Huang, Paul C Lott, Donglei Hu, Valentina A Zavala, Zoeb N Jamal, Tatiana Vidaurre, Sandro Casavilca-Zambrano, Jeannie Navarro Vásquez, Carlos A Castañeda, Guillermo Valencia, Zaida Morante, Mónica Calderón, Julio E Abugattas, Hugo A Fuentes, Ruddy Liendo-Picoaga, Jose M Cotrina, Silvia P Neciosup, Patricia Rioja Viera, Luis A Salinas, Marco Galvez-Nino, Scott Huntsman, Sixto E Sanchez, Michelle A Williams, Bizu Gelaye, Ana P Estrada-Florez, Guadalupe Polanco-Echeverry, Magdalena Echeverry, Alejandro Velez, Jenny A Carmona-Valencia, Mabel E Bohorquez-Lozano, Javier Torres, Miguel Cruz, Weang-Kee Ho, Soo Hwang Teo, Mei Chee Tai, Esther M John, Christopher A Haiman, David V Conti, Fei Chen, Gabriela Torres-Mejía, Lawrence H Kushi, Susan L Neuhausen, Elad Ziv, Luis G Carvajal-Carmona, Laura Fejerman","doi":"10.1158/1055-9965.EPI-24-1247","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1247","url":null,"abstract":"<p><strong>Background: </strong>A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European and Asian ancestry, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L specific variants among self-reported H/L women.</p><p><strong>Methods: </strong>PRS performance was evaluated using multivariable logistic regression and the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Both European and Asian PRSs performed worse in H/L samples compared to original reports. The best European PRS performed better than the best Asian PRS in pooled H/L samples. European PRSs had decreased performance with increasing Indigenous American (IA) ancestry while Asian PRSs had increased performance with increasing IA ancestry. The addition of 2 H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry and did not impact the performance of PRSs in individuals with lower IA ancestry.</p><p><strong>Conclusions: </strong>A single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry specific panels, could be used in clinical practice.</p><p><strong>Impact: </strong>Results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry specific variants into PRS for clinical application.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Paradox of Poor Cervical Cancer Screening Uptake for Kidney Transplant Recipients.
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-1033
Adnan Sharif
{"title":"The Paradox of Poor Cervical Cancer Screening Uptake for Kidney Transplant Recipients.","authors":"Adnan Sharif","doi":"10.1158/1055-9965.EPI-24-1033","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1033","url":null,"abstract":"<p><p>Kidney transplant recipients have an increased risk for developing and dying from cervical cancer compared with the general population due to their immunosuppressed state. As one of the cancers most amenable to an effective screening program, encouraging eligible women after transplantation to adhere to screening is critically important. Therefore, the observation that kidney transplant recipients may have a lower uptake of cervical cancer screening compared with the general population is concerning. The reasons for this should be studied so that any barriers can be identified and overcome. Kidney transplant recipients and recipients of other solid organ allografts must be encouraged and supported to adhere to recommended screening programs to mitigate the morbidity and mortality of posttransplantation cancer. See related article by Hsu et al., p. 1678.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"33 12","pages":"1544-1546"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of High-Incidence Populations in the United States for Anti-Epstein-Barr Virus Serologic Screening for Nasopharyngeal Carcinoma. 确定美国鼻咽癌抗爱泼斯坦巴氏病毒血清学筛查的高发人群。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-0576
Payton E Clark, Kekoa Taparra, Jacob A Miller
{"title":"Identification of High-Incidence Populations in the United States for Anti-Epstein-Barr Virus Serologic Screening for Nasopharyngeal Carcinoma.","authors":"Payton E Clark, Kekoa Taparra, Jacob A Miller","doi":"10.1158/1055-9965.EPI-24-0576","DOIUrl":"10.1158/1055-9965.EPI-24-0576","url":null,"abstract":"<p><strong>Background: </strong>In the United States, Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) disproportionately impacts Asian Americans (AA) and Native Hawaiians and other Pacific Islanders (NHPI) who have no access to screening. EBV-based screening trials in Asia have detected most cases at early stages. We sought to identify a US target population for NPC screening and hypothesized that once-lifetime screening could be cost-effective.</p><p><strong>Methods: </strong>We obtained NPC incidence data from the Surveillance, Epidemiology, and End Results Asian and Pacific Islander datasets. We estimated the number needed to screen (NNS), mortality reduction, and resource utilization using a validated model and performance data from trials. Six evaluated strategies incorporated serology, nasopharyngeal swab PCR, and endoscopy or MRI.</p><p><strong>Results: </strong>Intermediate-incidence and high-incidence populations accounted for 10.7% of US person-years yet 42.7% of cases. Anti-BNLF2b screening with selective endoscopy was the preferred strategy. In high-incidence populations, the median NNS to detect one case was 1,992, with a median of 7.12 NPC deaths averted per 100,000 screened. Screening met the willingness-to-pay threshold in all five high-incidence populations (median incremental cost-effectiveness ratio/gross domestic product, 0.82) and among men in intermediate-incidence populations.</p><p><strong>Conclusions: </strong>Nearly half of NPC in the United States arises among the 10% with AA or NHPI ethnicity. A suitable target population for US screening trials would be men and women aged 35 to 65 years of Chinese, Sāmoan, or Southeast Asian ethnicity, or men aged 35 to 60 years of Guamanian/Chamorro, Filipino, or Native Hawaiian ethnicity. Once-lifetime anti-BNLF2b screening could be cost-effective.</p><p><strong>Impact: </strong>These data may aid the design of US screening trials. Targeted NPC screening might mitigate health disparities.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1706-1716"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research. 北卡罗来纳大学癌症幸存者队列:幸存者合作研究资源。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-0794
Chelsea Anderson, Jeannette T Bensen, Emma H Allott, Patricia V Basta, Debra E Irwin, Adrian Gerstel, Laura Farnan, Hung-Jui Tan, Erin E Kent, Tzy-Mey Kuo, Christopher D Baggett, Andrew F Olshan, H Shelton Earp, Hazel B Nichols
{"title":"The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research.","authors":"Chelsea Anderson, Jeannette T Bensen, Emma H Allott, Patricia V Basta, Debra E Irwin, Adrian Gerstel, Laura Farnan, Hung-Jui Tan, Erin E Kent, Tzy-Mey Kuo, Christopher D Baggett, Andrew F Olshan, H Shelton Earp, Hazel B Nichols","doi":"10.1158/1055-9965.EPI-24-0794","DOIUrl":"10.1158/1055-9965.EPI-24-0794","url":null,"abstract":"<p><strong>Background: </strong>Rapid growth in the number of US cancer survivors drives the need for ongoing research efforts to improve outcomes and experiences after cancer. In this study, we describe the University of North Carolina (UNC) Cancer Survivorship Cohort, a medical center-based cohort of adults with cancer that integrates medical record-abstracted cancer information, patient-reported outcomes, and biological specimens.</p><p><strong>Methods: </strong>Participants ages 18+ were recruited from UNC oncology clinics between April 2010 and August 2016. After enrollment, participants completed questionnaires on a range of topics including demographics, health history, healthcare access and utilization, quality of life, and symptoms. Blood samples and tumor tissue specimens were collected and processed by study staff, and cancer characteristics and other clinical data were abstracted from electronic medical records. Participants consented to recontact for future studies and linkage of their data with other data resources.</p><p><strong>Results: </strong>In total, 3,999 participants with a cancer diagnosis were enrolled in the cohort. The most common cancer types among those enrolled included breast (N = 866), uterine (N = 458), colorectal (N = 300), prostate (N = 296), and head and neck (N = 248) cancers. Blood specimens were collected for 3,027 participants (76%). Additional participants without cancer (N = 1,299) were also enrolled, and the majority (62%) provided biospecimen samples.</p><p><strong>Conclusions: </strong>We encourage a wide collaboration with investigators across institutions seeking to advance research in cancer survivorship. Procedures are in place to support proposals for use of existing or linked data and for proposals that require participant recontact or analysis of biospecimens.</p><p><strong>Impact: </strong>The UNC Cancer Survivorship Cohort is a unique resource for cancer survivorship research.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1556-1563"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tobacco Biomarkers by Latino Heritage and Race, US, 2007 to 2014 National Health and Nutrition Examination Survey. 按拉丁裔血统和种族划分的烟草生物标志物,美国,2007-2014 年全国健康与营养调查。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-0744
Chelsea Duong, Erik J Rodriquez, Amanda S Hinerman, Somy Hooshmand, Sophie E Claudel, Neal L Benowitz, Eliseo J Pérez-Stable
{"title":"Tobacco Biomarkers by Latino Heritage and Race, US, 2007 to 2014 National Health and Nutrition Examination Survey.","authors":"Chelsea Duong, Erik J Rodriquez, Amanda S Hinerman, Somy Hooshmand, Sophie E Claudel, Neal L Benowitz, Eliseo J Pérez-Stable","doi":"10.1158/1055-9965.EPI-24-0744","DOIUrl":"10.1158/1055-9965.EPI-24-0744","url":null,"abstract":"<p><strong>Background: </strong>Tobacco biomarkers reflect smoking intensity and are used to assess cessation status. No study has evaluated variation by Latino heritage.</p><p><strong>Methods: </strong>Data from the 2007 to 2014 National Health and Nutrition Examination Survey were used to evaluate geometric mean concentrations of serum cotinine and urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), stratified by smoking status and race and ethnicity, and ROC curves estimated values to distinguish smokers from nonsmokers by race and ethnicity and Latino heritage.</p><p><strong>Results: </strong>The sample (n = 18,597) was 50.1% female, 16.6% Latino (58.6% Mexican, 10.4% Central American, 9.1% South American, 7.3% Puerto Rican, 3.5% Dominican, 2.7% Cuban, and 8.4% other Latinos, overall), 12.7% Black, and 70.7% White. Black nonsmokers and smokers had the highest cotinine concentrations (0.1 and 177.1 ng/mL), and among nonsmokers, Black individuals had the highest NNAL concentrations (1.4 pg/mL). Latino smokers had the lowest cotinine (32.7 ng/mL) and NNAL (63.9 pg/mL) concentrations. Among Latino smokers, Puerto Rican individuals had higher concentrations of cotinine (100.0 ng/mL) and NNAL (136.4 pg/mL). Cotinine levels defining smoking (Black: 9.1 ng/mL; Latino: 0.9 ng/mL; White: 3.8 ng/mL) and NNAL (Black: 24.1 pg/mL; Latino: 5.7 pg/mL; White: 15.5 pg/mL) varied. Puerto Rican adults (cotinine: 8.5 ng/mL; NNAL: 17.2 pg/mL) had higher levels than Central American (cotinine: 1.0 ng/mL, NNAL: 5.5 pg/mL) and Mexican (cotinine: 0.9 ng/mL, NNAL: 6.0 pg/mL) adults.</p><p><strong>Conclusions: </strong>Cotinine and NNAL concentrations that define smoking differed by race and ethnicity and by heritage among Latinos, showing meaningful differences.</p><p><strong>Impact: </strong>Cessation interventions with biomarker validation need to consider Latino heritage.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1586-1597"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Incidence of Gastric Cancer in El Salvador: A National Multisectorial Study during 2000 to 2014. 萨尔瓦多胃癌发病率高:2000-2014年全国多部门研究》。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-23-1459
Lisseth Ruiz de Campos, Marisabel Valdez de Cuellar, Dalton A Norwood, Tiffany Y Carrasco, Eleazar E Montalvan-Sanchez, Maria-Virginia Rodriguez Funes, Timothy Beasley, Ricardo L Dominguez, Luis E Bravo, Douglas R Morgan
{"title":"High Incidence of Gastric Cancer in El Salvador: A National Multisectorial Study during 2000 to 2014.","authors":"Lisseth Ruiz de Campos, Marisabel Valdez de Cuellar, Dalton A Norwood, Tiffany Y Carrasco, Eleazar E Montalvan-Sanchez, Maria-Virginia Rodriguez Funes, Timothy Beasley, Ricardo L Dominguez, Luis E Bravo, Douglas R Morgan","doi":"10.1158/1055-9965.EPI-23-1459","DOIUrl":"10.1158/1055-9965.EPI-23-1459","url":null,"abstract":"<p><strong>Background: </strong>Gastric adenocarcinoma is the fourth leading cause of global cancer mortality and leading infection-associated cancer. Gastric cancer has significant geographic variability, with a high incidence in East Asia and mountainous regions of Latin America. In the United States, gastric cancer represents a marked disparity with incidence rates that are two to three times higher in Hispanics compared to non-Hispanic Whites.</p><p><strong>Methods: </strong>We conducted a national retrospective study of incident gastric cancer in El Salvador from to 2000 to 2014 to estimate the age-standardized incidence rate (ASIR) by using a combination of pathology and endoscopy databases. A unique multisectorial coalition was formed between the Ministry of Health (MINSAL) and ES Gastroenterology Society (AGEDES), representing public hospitals (n = 5), governmental employee hospitals (ISSS, n = 5), and private facilities (n = 6), accounting for >95% of national endoscopy capacity. HER2 and EBV tumor status was ascertained in a representative sample during 2014 to 2016.</p><p><strong>Results: </strong>A total of 10,039 unique cases of gastric cancer were identified, 45.5% female, and mean age of 65. 21% and 9.4% were <55 and <45 years old, respectively. ASIRs (M, F) were 18.9 (95% CI, 14.4-20.7) and 12.2 per 100,000 persons (95% CI, 10.9-13.5), respectively, in the period 2010 to 2014 with all centers operational. Intestinal gastric cancer was 2.8 times more common than diffuse gastric cancer; 23.2% had partial or complete pyloric obstruction. The HER2 2+/3+ status was 16.7% and EBV-encoded RNA positivity was 10.2%.</p><p><strong>Conclusions: </strong>A high incidence of gastric cancer was confirmed in El Salvador and nearly half of the patients were female.</p><p><strong>Impact: </strong>The findings have implications for cancer control in the Central America LMICs and for US Latino populations. See related commentary by Riquelme and Abnet, p. 1550.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1571-1577"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis. 血浆胃泌素与性别特异性、部位特异性和早发性结直肠癌的风险:孟德尔随机分析
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-0926
Emma Hazelwood, Catalina Lopez Manzano, Emma E Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, Laura Anderson, Marc J Gunter, Neil Murphy, Bethany Van Guelpen, Nikos Papadimitriou
{"title":"Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis.","authors":"Emma Hazelwood, Catalina Lopez Manzano, Emma E Vincent, Demetrius Albanes, David Timothy Bishop, Loïc Le Marchand, Cornelia M Ulrich, Ulrike Peters, Gwen Murphy, Niloy Jewel Samadder, Laura Anderson, Marc J Gunter, Neil Murphy, Bethany Van Guelpen, Nikos Papadimitriou","doi":"10.1158/1055-9965.EPI-24-0926","DOIUrl":"10.1158/1055-9965.EPI-24-0926","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis.</p><p><strong>Methods: </strong>Genetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied.</p><p><strong>Results: </strong>We found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81-1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer.</p><p><strong>Conclusions: </strong>Our study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite-stratified colorectal cancer risk.</p><p><strong>Impact: </strong>This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1727-1732"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance.
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-1405
Lindor Qunaj, Suzanne Lentzsch, Alfred I Neugut
{"title":"The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance.","authors":"Lindor Qunaj, Suzanne Lentzsch, Alfred I Neugut","doi":"10.1158/1055-9965.EPI-24-1405","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1405","url":null,"abstract":"<p><p>The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies. Although precursor clinical states are not well-established for most hematologic malignancies, multiple myeloma is a notable exception. Virtually all patients with multiple myeloma first develop monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic but easily detectable condition. However, broad screening for MGUS has not been adopted primarily because there is no proven intervention to delay or prevent the progression of MGUS to multiple myeloma. Furthermore, the incidence of MGUS is poorly understood; a better understanding of its epidemiology will be critical in designing appropriate screening guidelines once an effective treatment has been developed. In the current issue of Cancer Epidemiology, Biomarkers & Prevention, Ji and colleagues provide important epidemiologic insights on MGUS, including a critical discussion on how its incidence and preclinical duration vary by age and race, acknowledging that both MGUS and multiple myeloma are more common in Black than White populations. See related article by Ji et al., p. 1690.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":"33 12","pages":"1547-1549"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Gastric Cancer Mortality and Years of Life Lost in Nicaragua: A Population-Based Study 1997 to 2012. 尼加拉瓜的高胃癌死亡率和生命损失年数:1997-2012年基于人口的研究》。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-23-1392
Edgar M Peña-Galo, Guillermo Palacios-Navarro, Javier Pastora-Membreño, Tatiana Torres-Herman, Dalton A Norwood, Eleazar E Montalvan-Sanchez, Timothy Beasley, Luis E Bravo, Douglas R Morgan
{"title":"High Gastric Cancer Mortality and Years of Life Lost in Nicaragua: A Population-Based Study 1997 to 2012.","authors":"Edgar M Peña-Galo, Guillermo Palacios-Navarro, Javier Pastora-Membreño, Tatiana Torres-Herman, Dalton A Norwood, Eleazar E Montalvan-Sanchez, Timothy Beasley, Luis E Bravo, Douglas R Morgan","doi":"10.1158/1055-9965.EPI-23-1392","DOIUrl":"10.1158/1055-9965.EPI-23-1392","url":null,"abstract":"<p><strong>Background: </strong>Gastric adenocarcinoma is the fourth leading cause of cancer-related mortality and leading infection-associated cancer. Gastric adenocarcinoma has striking geographic variability, with high incidence in East Asia and mountainous Latin America. Reliable cancer data and population-based cancer registries are lacking for the majority of low- and middle-income countries, including the Central American Four region (CA-4, Nicaragua, El Salvador, Honduras, and Guatemala).</p><p><strong>Methods: </strong>Mortality data for Nicaragua were obtained from the highly rated Ministry of Health death registry. All the patients were diagnosed with gastric cancer between 1997 and 2012 (ICD-10 codes, C16.0-C16.9) and death due to any cause were included in the study. Data on variables such as sex, age (stratified by 5-year age groups), municipality, urban/rural, altitude, and year of death were analyzed.</p><p><strong>Results: </strong>A total of 3,886 stomach cancer deaths were reported in Nicaragua between 1997 and 2012, of which 2,214 (56.9%) were male. The age-standardized mortality rates were 13.1 and 8.7 per 100,000 habitants for males and females, respectively, and without significant change during the study period (annual percentage change = -0.7, P = 0.2). An average of 17.9 years were lost per death, accounting for 67,964 years of life lost (YLL).</p><p><strong>Conclusions: </strong>The burden of gastric cancer mortality is high in Nicaragua with a significantly elevated age-standardized mortality rate, YYL, and average YLL.</p><p><strong>Impact: </strong>The projected increase in mortality portends the double cancer burden in northern Central America, with persistent infection-associated cancers and growing transition cancers (e.g., breast and colon cancers), which has implications for cancer control in Mesoamerica and US Latino populations. See related commentary by Riquelme and Abnet, p. 1550.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1564-1570"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adiposity throughout Adulthood and Risk of Young-Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study. 年轻女性健康史研究》中成年后的肥胖与年轻乳腺癌肿瘤亚型的风险。
IF 3.7 3区 医学
Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-02 DOI: 10.1158/1055-9965.EPI-24-1067
Lydia Marcus Post, Dorothy R Pathak, Ann S Hamilton, Kelly A Hirko, Richard T Houang, Emily H Guseman, Dan Sanfelippo, Nicole Bohme Carnegie, L Karl Olson, Hallgeir Rui, Ann G Schwartz, Ellen M Velie
{"title":"Adiposity throughout Adulthood and Risk of Young-Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study.","authors":"Lydia Marcus Post, Dorothy R Pathak, Ann S Hamilton, Kelly A Hirko, Richard T Houang, Emily H Guseman, Dan Sanfelippo, Nicole Bohme Carnegie, L Karl Olson, Hallgeir Rui, Ann G Schwartz, Ellen M Velie","doi":"10.1158/1055-9965.EPI-24-1067","DOIUrl":"10.1158/1055-9965.EPI-24-1067","url":null,"abstract":"<p><strong>Background: </strong>The role of adult adiposity in young-onset breast cancer (YOBC) subtype risk is not well understood.</p><p><strong>Methods: </strong>In this population-based case (n = 1812)-control (n = 1,381) study of invasive YOBC (ages <50 years), cases were identified from the Los Angeles County and Metropolitan Detroit Surveillance, Epidemiology, and End Results registries, 2010 to 2015. Area-based, frequency-matched controls were sampled from the 2010 Census. General adiposity [body mass index (BMI)] and central adiposity (waist circumference and waist-to-height ratio) across adulthood and covariates were collected from in-person interviews and measurements. ORs and 95% confidence intervals (CI) for adiposity and YOBC tumor subtypes [i.e., luminal A, luminal B, HER2+, and triple negative (TN)] were calculated, overall and by parity, using multivariable weighted logistic regression.</p><p><strong>Results: </strong>Obese young adult BMI was inversely associated with luminal A YOBC (OR = 0.35, 95% CI, 0.16-0.79); other subtype associations were nonsignificant. Similarly, adult overweight and obese BMIs were inversely associated with luminal A (OR = 0.66, 95% CI, 0.48-0.91 and OR = 0.59, 95% CI, 0.46-0.87, respectively), but not other subtypes. Conversely, larger waist circumference was associated with higher odds of luminal B and TN YOBC (OR = 1.48, 95% CI, 1.01-2.15 and OR = 2.48, 95% CI, 1.52-3.88, respectively), but not other subtypes (with similar results for weight-to-height ratio); highest odds were among parous women.</p><p><strong>Conclusions: </strong>Findings show greater general adult adiposity is associated with reduced odds of luminal A YOBC, whereas greater central adiposity is associated with increased odds of luminal B and TN YOBC, particularly among parous women.</p><p><strong>Impact: </strong>Additional studies of central adiposity and YOBC subtype risk, especially incorporating pregnancy history, are warranted.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"1659-1670"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信